Agios Pharmaceuticals AGIO Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's operating lease right-of-use assets in other assets?
- Agios Pharmaceuticals (AGIO) reported operating lease right-of-use assets in other assets of $27.2M in Q1 2026.
- How has Agios Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Agios Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 31.8% year-over-year, from $39.86M to $27.2M.
- What is the long-term trend for Agios Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a -18.5% compound annual growth rate (CAGR), from $84.66M to $30.45M.